COMMUNIQUÉS West-GlobeNewswire

Transactions in connection with share buy-back program
04/08/2026
Company announcement no. 28 - 26 04 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
04/08/2026
Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor BRISBANE, Calif., Aug. 04, 2026 (GLOBE [...]
Rapid Nutrition Joins Global Conversation on the Future of AI-Driven HealthTech
04/08/2026
Growing recognition across leading international business media highlights increasing interest in the convergence of artificial intelligence, personalized wellness and digital health. LONDON, Aug. 03, 2026 (GLOBE [...]
Communiqué de presse : MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques
04/08/2026
MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques Paris, le 4 août 2026. Sanofi a annoncé aujourd’hui que la [...]
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
04/08/2026
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an [...]
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China
04/08/2026
BEIJING, Aug. 03, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that orelabrutinib [...]
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
03/08/2026
Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million [...]
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
03/08/2026
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
03/08/2026
August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune [...]
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
03/08/2026
MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
03/08/2026
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2 newly- [...]
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026
03/08/2026
REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the [...]
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
03/08/2026
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company [...]
Keros Therapeutics Reports Second Quarter 2026 Financial Results
03/08/2026
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
03/08/2026
BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity [...]
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
03/08/2026
Delivered ~ 15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of [...]

Pages